文献速递血栓与止血

儿童难治性免疫性血小板减少症新定义与管理方法的提案:来自洲际免疫性血小板减少症研究组的思考

A proposal for new definition (s) and management approach to paediatric refractory ITP: Reflections from the Intercontinental ITP Study Group.
PubMed 文献 · Br J Haematol · 2023-08-29

儿童免疫性血小板减少症(ITP)多较轻微且自限,多数患儿在诊断后12个月内血小板计数恢复正常。静脉注射免疫球蛋白(IVIG)或糖皮质激素治疗高效(IVIG >80%,糖皮质激素 >95%),二线促血小板生成素受体激动剂和利妥昔单抗应答率均 >60%。本文综述儿童难治性ITP(rITP)的临床特征,提出分类建议并探索潜在预测因素。

要点

  • 儿童ITP多数在诊断后12个月内血小板计数恢复正常,许多患儿无需治疗即可观察。
  • 需要治疗时,IVIG应答率 >80%,糖皮质激素应答率 >95%。
  • 二线促血小板生成素受体激动剂和利妥昔单抗应答率均 >60%。

核心结论

  • 本文综述儿童难治性ITP的临床特征,提出分类建议并探索潜在预测因素。

研究设计与样本

  • 本文为洲际ITP研究组的综述,检索范围原文未报告。

主要发现

  • 儿童ITP多数为轻度自限性疾病,多数患儿在诊断后12个月内血小板计数恢复正常。
  • 许多ITP患儿可仅观察而无需治疗。
  • 需要治疗时,IVIG应答率 >80%,糖皮质激素应答率 >95%。
  • 二线促血小板生成素受体激动剂和利妥昔单抗的应答率均 >60%。
  • 部分儿童仍会出现难治性ITP,对升血小板治疗应答差或短暂。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune thrombocytopenia (ITP) in children is a relatively mild and self-limited disorder with the majority of children demonstrating normalization of platelet count by 12 months from diagnosis. Because of this, many children with ITP can be observed without the need for treatment. When needed, treatment with either intravenous immunoglobulin (IVIG) or corticosteroids is highly effective (>80% IVIG and >95% corticosteroids). For those children who require second-line therapies, response rates of >60% are seen with both the thrombopoietin-receptor agonists and rituximab. Despite this, some children will have 'refractory' ITP (rITP) with poor or transient responses to platelet-raising therapies. Here, we review the clinical features of rITP in children, outline proposed classifications and explore potential predictors for children with rITP.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Neunert C, Heitink-Polle KMJ, Lambert MP, et al. A proposal for new definition (s) and management approach to paediatric refractory ITP: Reflections from the Intercontinental ITP Study Group. Br J Haematol. 2023. PMID: 37641973. doi:10.1111/bjh.19072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。